VJOncology is committed to improving our service to you

WCCS/EADO 2016 | Why dynamic heterogeneity is important for designing drugs in melanoma

VJOncology is committed to improving our service to you

Nikolas Haass

Nikolas Haass, MD, PhD of the University of Queensland, Brisbane, Australia discusses the work of his lab on dynamic heterogeneity in the context of melanoma and his talk given at the 2016 World Congress on Cancers of the Skin (WCCS) and the Congress of the European Association of Dermato-Oncology (EADO) in Vienna, Austria. According to Prof. Haass, dynamic heterogeneity is important for designing drugs as different sub-populations of tumor cells within a tumor may respond differently to certain drugs. In his lab, the aim is to understand the biology of the different sub-populations of tumor cells. He further elaborates on the expertise of the lab, which is 3D cell culture and explains the real-time cell cycle imaging technique, which can be used to make 4D videos of tumors to help differentiate the sub-populations of tumor cells.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter